{"article_title": "Sandoz Submits Third Biosimilar Application To FDA", "article_keywords": ["fda", "biosimilar", "submission", "wednesdaythe", "submits", "biologics", "application", "york", "pegfilgrastim", "sandoz", "view"], "article_url": "http://www.law360.com/articles/728639/sandoz-submits-third-biosimilar-application-to-fda", "article_text": "Sandoz Submits Third Biosimilar Application To FDA\n\nLaw360, New York (November 18, 2015, 8:37 PM ET) -- The U.S. Food and Drug Administration has accepted a biologics license application from Novartis-owned Sandoz Inc. for a biosimilar that would help cancer patients receiving chemotherapy fight off infection, the drugmaker announced Wednesday.\n\n\n\nThe application for the biosimilar for Amgen Inc.\u2019s Neulasta, or pegfilgrastim, comes just over two months after Sandoz launched the country's first biosimilar through the Affordable Care Act\u2019s biosimilar pathway, known as the Biologics Price Competition and Innovation Act.\n\n\n\n\u201cThe FDA\u2019s acceptance of our regulatory submission for biosimilar pegfilgrastim \u2014 our third biosimilar...\n\nTo view the full article, register now.", "article_metadata": {"description": "The U.S. Food and Drug Administration has accepted a biologics license application from Novartis-owned Sandoz Inc. for a biosimilar that would help cancer patients receiving chemotherapy fight off infection, the drugmaker announced Wednesday.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/728639/sandoz-submits-third-biosimilar-application-to-fda", "csrf-token": "ofvhnpzPJtI7uDIhsUoHAS+rIM69zI++NbIotFA6yoO2PnnLfKc9svDciQ2mQlXF6I0R1fLAqKOoharZXdx3ng==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/728639/sandoz-submits-third-biosimilar-application-to-fda", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Sandoz Submits Third Biosimilar Application To FDA - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fda335\"", "article_summary": "Sandoz Submits Third Biosimilar Application To FDALaw360, New York (November 18, 2015, 8:37 PM ET) -- The U.S. Food and Drug Administration has accepted a biologics license application from Novartis-owned Sandoz Inc. for a biosimilar that would help cancer patients receiving chemotherapy fight off infection, the drugmaker announced Wednesday.\n\u201cThe FDA\u2019s acceptance of our regulatory submission for biosimilar pegfilgrastim \u2014 our third biosimilar...To view the full article, register now.\nThe application for the biosimilar for Amgen Inc.\u2019s Neulasta, or pegfilgrastim, comes just over two months after Sandoz launched the country's first biosimilar through the Affordable Care Act\u2019s biosimilar pathway, known as the Biologics Price Competition and Innovation Act."}